CBIOHIGH SIGNALFINANCIAL10-K

CBIO underwent a major corporate transformation, reincorporating from Delaware to Cayman Islands while dramatically scaling operations with massive increases in cash, R&D spending, and losses.

The reincorporation to Cayman Islands combined with the 1,888% increase in cash suggests a major financing event or business combination that fundamentally transformed the company's capital structure. However, the simultaneous 868% surge in R&D expenses and tripling of net losses to $154M indicates aggressive expansion that significantly increases execution risk and cash burn rate.

Comparing 2026-02-26 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

CBIO experienced a dramatic financial transformation with cash and equivalents surging from $10.7M to $213.2M (+1,888%) and total assets growing to $240.3M, indicating a major capital infusion. However, this was accompanied by an explosive increase in R&D expenses from $14.3M to $138.1M (+868%) and net losses expanding from -$37.9M to -$153.9M. The massive cash raise provides runway but the quadrupled burn rate and operational scaling create significant execution risk for investors.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+9115.8%
$10K$919K

Capital expenditure jumped 9115.8% — major investment cycle underway; assess returns on deployment.

Stockholders Equity
Balance Sheet
+3720.6%
$5.3M$203.0M

Equity base grew 3720.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+2066.5%
$11.1M$240.3M

Asset base grew 2066.5% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+2033.7%
$11.1M$236.7M

Current assets grew 2033.7% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+1888.7%
$10.7M$213.2M

Cash position surged 1888.7% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
+868.4%
$14.3M$138.1M

R&D investment increased 868.4% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
+545.2%
$5.8M$37.3M

Liabilities grew 545.2% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+524.3%
$5.8M$36.1M

Current liabilities surged 524.3% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
-306.4%
-$37.9M-$153.9M

Net income declined 306.4% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-281.2%
-$40.0M-$152.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-13
ADDED
(Exact name of registrant as specified in its charter) ________________________________ Cayman Islands 06-1686563 (State or other jurisdiction of incorporation or organization) (I.R.S.
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and "emerging growth company" in Rule 12b-2 of the Exchange Act.
The number of the Registrant s Ordinary Shares outstanding as of February 23, 2026 was 27,556,767 .
Market for Registrant s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 103 Item 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 105 Item 7A .
+7 more — sign up free →
REMOVED
(Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) P.O.
See definitions of large accelerated filer, accelerated filer , smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
At February 7, 2025, 64,513,862 shares of GlycoMimetics, Inc.
s Common Stock, $0.001 par value per share, were outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations, but are also contained elsewhere in this Annual Report.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →